Cargando…
Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
SARS-CoV-2 is a newly identified member of the coronavirus family that has caused the Coronavirus disease 2019 (COVID-19) pandemic. This rapidly evolving and unrelenting SARS-CoV-2 has disrupted the lives and livelihoods of millions worldwide. As of 23 August 2021, a total of 211,373,303 COVID-19 ca...
Autores principales: | Pang, Natalie Yan-Lin, Pang, Alexander Shao-Rong, Chow, Vincent T., Wang, De-Yun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405719/ https://www.ncbi.nlm.nih.gov/pubmed/34465396 http://dx.doi.org/10.1186/s40779-021-00342-3 |
Ejemplares similares
-
Comparative evaluation and longevity of neutralising and binding antibodies for SARS-COV-2
por: Davidson, Natalie, et al.
Publicado: (2021) -
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants
por: Pallett, Scott J C, et al.
Publicado: (2022) -
Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation
por: Kemp, SA, et al.
Publicado: (2020) -
Sustained neutralising antibodies in the Wuhan population suggest durable protection against SARS-CoV-2
por: Strugnell, Richard, et al.
Publicado: (2021) -
AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC
por: Wall, Emma C, et al.
Publicado: (2021)